DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer

UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced the appointment of David Liebowitz, M.D., Ph.D., an industry veteran with over 20 years of experience in oncology drug and viral vaccine development, as chief medical officer.   

“We are thrilled to welcome Dave to the executive leadership team at DNAtrix,” said Jeffrey Knapp, chief executive officer of DNAtrix. “Dave has expertise in developing products that elicit immune responses against targets of interest through various therapeutic modalities, including viral-based vaccines. His deep experience leading oncology drug development programs for innovative, young, as well as established biopharmaceutical companies ­­– such as Amgen — will prove invaluable as we advance our pipeline with multiple product candidates being studied in several tumor types and two programs in pivotal stage development.”

Learn more about DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer.

---

In related news

DNAtrix Presents Positive Results From Study at the 2019 SNO Annual Meeting

DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer (PR Newswire)

DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial (PR Newswire)

DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors Published in Clinical Cancer Research